Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
PMID: 28242111 www.ncbi.nlm.nih.gov/pubmed/28242111
Informally, media, patients, and even some physicians have dubbed GLP-1 medications as miracle drugs because of the profound weight loss among users
R.Steinberg, Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression, Diabetes, Obesity and Metabolism (2026): 115, #MASLD #MASH #LiverHealth #MetabolicHealth #GLP1 #Obesity #Diabetes #Hepatology To view or add a comment, sign in Here the authors propose therapeutic advancement of the adipokine Adissp, an adipokine without a known receptor, that promotes an insulin-independent mechanism for glucose uptake and augments thermogenesis, representing a promising class of therapeutics for concurrently and synergistically treating insulin resistance, diabetes, obesity, and associated comorbidities
Of course, we have words for things like that: steroids, doping, performance-enhancing drugs, and the like
